Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Racemetyrosine - Tyme Technologies

Drug Profile

Racemetyrosine - Tyme Technologies

Alternative Names: SM-88; SM-88i; SM-88n

Latest Information Update: 09 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tyme Technologies
  • Developer The Joseph Ahmed Foundation; Tyme Technologies
  • Class Amino acids; Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Pancreatic cancer
  • Phase II Ewing's sarcoma; Prostate cancer
  • Preclinical Breast cancer; Cancer; Glioma; Osteosarcoma

Most Recent Events

  • 08 Jan 2020 Tyme Technologies enters into co-promotion agreement with Eagle Pharmaceuticals in USA
  • 04 Nov 2019 Tyme Technologies plans the phase II/III PanCAN-Precision-PromiseSM trial for Pancreatic cancer (Metaststic disease, Second-line therapy or greater) in USA by year end 2019
  • 04 Nov 2019 Tyme Technologies plans a pivotal phase III trial for Pancreatic cancer (Metastatic disease, Second-line therapy or greater) by end of 2019 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top